David A. Boltz

2.7k total citations
36 papers, 2.1k citations indexed

About

David A. Boltz is a scholar working on Epidemiology, Infectious Diseases and Immunology. According to data from OpenAlex, David A. Boltz has authored 36 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Epidemiology, 9 papers in Infectious Diseases and 9 papers in Immunology. Recurrent topics in David A. Boltz's work include Influenza Virus Research Studies (23 papers), Respiratory viral infections research (13 papers) and Animal Disease Management and Epidemiology (7 papers). David A. Boltz is often cited by papers focused on Influenza Virus Research Studies (23 papers), Respiratory viral infections research (13 papers) and Animal Disease Management and Epidemiology (7 papers). David A. Boltz collaborates with scholars based in United States, Japan and Russia. David A. Boltz's co-authors include Robert G. Webster, Richard J. Smeyne, Haeman Jang, Elena A. Govorkova, Jerry R. Aldridge, Kennie R. Shepherd, Yun Jiao, Katharine Sturm‐Ramirez, John Franks and Paul G. Thomas and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Neuroscience and PLoS ONE.

In The Last Decade

David A. Boltz

34 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David A. Boltz United States 20 1.1k 642 575 481 322 36 2.1k
Martha McGregor United States 17 856 0.8× 459 0.7× 380 0.7× 420 0.9× 111 0.3× 20 1.6k
Maxim C.‐J. Cheeran United States 28 951 0.9× 619 1.0× 690 1.2× 570 1.2× 122 0.4× 57 2.8k
Romain Volmer France 18 727 0.7× 325 0.5× 243 0.4× 572 1.2× 126 0.4× 38 1.7k
Shengbo Cao China 32 451 0.4× 1.2k 1.9× 644 1.1× 794 1.7× 71 0.2× 125 3.0k
Stephanie J. Bissel United States 24 582 0.6× 554 0.9× 468 0.8× 509 1.1× 111 0.3× 48 1.7k
Wouter Koudstaal Netherlands 16 1.2k 1.1× 576 0.9× 614 1.1× 574 1.2× 70 0.2× 29 2.2k
Kristina Eriksson Sweden 24 575 0.5× 260 0.4× 882 1.5× 427 0.9× 174 0.5× 52 2.1k
Isamu Mori Japan 26 662 0.6× 326 0.5× 722 1.3× 644 1.3× 100 0.3× 80 2.1k
Edward M. Campbell United States 30 827 0.8× 818 1.3× 992 1.7× 1.2k 2.6× 349 1.1× 67 3.4k
Xuexing Zheng China 24 421 0.4× 596 0.9× 202 0.4× 349 0.7× 59 0.2× 71 1.5k

Countries citing papers authored by David A. Boltz

Since Specialization
Citations

This map shows the geographic impact of David A. Boltz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Boltz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Boltz more than expected).

Fields of papers citing papers by David A. Boltz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Boltz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Boltz. The network helps show where David A. Boltz may publish in the future.

Co-authorship network of co-authors of David A. Boltz

This figure shows the co-authorship network connecting the top 25 collaborators of David A. Boltz. A scholar is included among the top collaborators of David A. Boltz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David A. Boltz. David A. Boltz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Ying, Chen Yang, Yutong Song, et al.. (2021). Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy. Proceedings of the National Academy of Sciences. 118(29). 106 indexed citations
2.
Stauft, Charles B., Chen Yang, J. Robert Coleman, et al.. (2019). Live-attenuated H1N1 influenza vaccine candidate displays potent efficacy in mice and ferrets. PLoS ONE. 14(10). e0223784–e0223784. 23 indexed citations
3.
Činátl, Jindřich, David A. Boltz, Xiang Peng, et al.. (2018). Antiviral effect of a derivative of isonicotinic acid enisamium iodide (FAV00A) against influenza virus. Acta Virologica. 62(2). 191–195. 12 indexed citations
4.
Hatta, Yasuko, David A. Boltz, Sally R. Sarawar, et al.. (2018). Novel influenza vaccine M2SR protects against drifted H1N1 and H3N2 influenza virus challenge in ferrets with pre-existing immunity. Vaccine. 36(33). 5097–5103. 28 indexed citations
5.
Hatta, Yasuko, David A. Boltz, Sally R. Sarawar, et al.. (2017). M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza. Vaccine. 35(33). 4177–4183. 29 indexed citations
6.
Bayne, Anne-Cécile V., David A. Boltz, Parastoo Azadi, et al.. (2013). Vaccination against Influenza with Recombinant Hemagglutinin Expressed by Schizochytrium sp. Confers Protective Immunity. PLoS ONE. 8(4). e61790–e61790. 39 indexed citations
7.
Shiratori, Ikuo, et al.. (2013). Selection of DNA aptamers that bind to influenza A viruses with high affinity and broad subtype specificity. Biochemical and Biophysical Research Communications. 443(1). 37–41. 83 indexed citations
8.
Jang, Haeman, David A. Boltz, Jennifer McClaren, et al.. (2012). Inflammatory Effects of Highly Pathogenic H5N1 Influenza Virus Infection in the CNS of Mice. Journal of Neuroscience. 32(5). 1545–1559. 94 indexed citations
9.
Wang, Jingxin, David A. Boltz, Janet E. McElhaney, et al.. (2011). No evidence of a link between influenza vaccines and Guillain–Barre syndrome–associated antiganglioside antibodies. Influenza and Other Respiratory Viruses. 6(3). 159–166. 15 indexed citations
10.
Boltz, David A., Jerry R. Aldridge, Robert G. Webster, & Elena A. Govorkova. (2010). Drugs in Development for Influenza. Drugs. 70(11). 1349–1362. 106 indexed citations
11.
Duan, Susu, David A. Boltz, Patrick Seiler, et al.. (2010). Oseltamivir–Resistant Pandemic H1N1/2009 Influenza Virus Possesses Lower Transmissibility and Fitness in Ferrets. PLoS Pathogens. 6(7). e1001022–e1001022. 92 indexed citations
12.
Boltz, David A., Patrick Seiler, Elena A. Govorkova, et al.. (2009). Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao People's Democratic Republic. Journal of General Virology. 91(4). 949–959. 87 indexed citations
13.
Boltz, David A., Bounlom Douangngeun, Phouvong Phommachanh, et al.. (2009). Field assessment of an H5N1 inactivated vaccine in chickens and ducks in Lao PDR. Archives of Virology. 154(6). 939–944. 19 indexed citations
14.
Jang, Haeman, David A. Boltz, Katharine Sturm‐Ramirez, et al.. (2009). Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration. Proceedings of the National Academy of Sciences. 106(33). 14063–14068. 358 indexed citations
15.
Boltz, David A., Jerold E. Rehg, Jennifer McClaren, Robert G. Webster, & Elena A. Govorkova. (2008). Oseltamivir Prophylactic Regimens Prevent H5N1 Influenza Morbidity and Mortality in a Ferret Model. The Journal of Infectious Diseases. 197(9). 1315–1323. 41 indexed citations
16.
Boltz, David A., et al.. (2008). Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice. Antiviral Research. 80(2). 150–157. 36 indexed citations
17.
Jang, Haeman, David A. Boltz, Robert G. Webster, & Richard J. Smeyne. (2008). Viral parkinsonism. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1792(7). 714–721. 216 indexed citations
18.
19.
Boltz, David A., Bounlom Douangngeun, Phouvong Phommachanh, et al.. (2006). H5N1 Influenza Viruses in Lao People's Democratic Republic. Emerging infectious diseases. 12(10). 1593–1595. 16 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Martha McGregor Breakdown of academic impact, for papers by Maxim C.‐J. Cheeran Breakdown of academic impact, for papers by Romain Volmer Breakdown of academic impact, for papers by Shengbo Cao Breakdown of academic impact, for papers by Stephanie J. Bissel Breakdown of academic impact, for papers by Wouter Koudstaal Breakdown of academic impact, for papers by Kristina Eriksson Breakdown of academic impact, for papers by Isamu Mori Breakdown of academic impact, for papers by Edward M. Campbell Breakdown of academic impact, for papers by Xuexing Zheng
Rankless by CCL
2026